VHL and renal cell carcinoma: In 2021, the HIF‐2α inhibitor belzutifan was approved as monotherapy for patients with VHL‐associated RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumor (pNET) based on the basket phase II trial (NCT03401788) showing an ORR of 49, 63, and 83%, respectively.